← Search & browse all drugs

iotrolan

V08AB06

Forms & Strengths

Intrathecal solution: 240 mg iodine/mL
Intrathecal solution: 280 mg iodine/mL
Intravascular solution: 300 mg iodine/mL

Adult Dosing

Myelography (lumbar/cervical): 5 mL to 15 mL of 240 mg/mL or 280 mg/mL solution, tailored to clinical region and technique
Ventriculography / Cisternography: 2 mL to 10 mL depending on target anatomical space

Pediatric Dosing

Myelography / Cisternography: Dosage is reduced based on age, body weight, and clinical condition; established by pediatric neuroradiology protocols
Safety and efficacy in neonates not fully established; use lowest effective diagnostic volume

Indications

Intrathecal administration for adult and pediatric myelography (lumbar, thoracic, cervical)
Cisternography and ventriculography
Contrast enhancement for computed tomography (CT) of the subarachnoid space

Mechanism of Action

Non-ionic, water-soluble, dimeric radiocontrast agent containing iodine
Absorbs X-radiation via bound iodine atoms, opacifying subarachnoid cerebrospinal fluid pathways for visualization on CT or X-ray imaging

Contraindications

Hypersensitivity to iotrolan or other iodinated contrast media
Manifest hyperthyroidism
Acute inflammatory pelvic disease
Symptomatic intracranial pressure elevation with impending herniation

Adverse Reactions

Headache (frequently post-lumbar puncture)
Nausea and vomiting
Dizziness, vertigo, and anxiety
Transient EEG changes or rare seizures associated with intrathecal administration
Back pain, neck stiffness, and meningismus

Drug Interactions

Concomitant neuroleptic drugs, MAO inhibitors, tricyclic antidepressants, or phenothiazines lower seizure threshold and increase risk when administered with intrathecal contrast
Beta-blockers may reduce efficacy of treatment for hypersensitivity reactions and bronchospasm
Interference with thyroid function radioisotope uptake tests for up to several weeks

Curated Content: Needs Vetting Before Put to Clinical Use